Global Antibody-Drug Conjugates Market
Description
MARKET OVERVIEW:
The global Antibody-Drug Conjugates Market is expected to expand at a CAGR of 14.7% from 2026 to 2034, driven by the rising demand for targeted oncology therapies, increasing approvals of next-generation ADCs, growing adoption across solid tumors, and strong pharmaceutical investment in linker-payload innovation. Antibody-drug conjugates have moved from a niche oncology modality into one of the most commercially attractive areas of cancer therapeutics, as they combine the targeting ability of monoclonal antibodies with the cell-killing strength of highly potent cytotoxic payloads.
ADCs are designed to deliver chemotherapy-like agents directly to cancer cells while reducing exposure to healthy tissues. This targeted delivery model addresses a long-standing limitation in oncology: achieving strong tumor control without the systemic toxicity associated with conventional chemotherapy. The technology has become especially important in breast cancer, lung cancer, urothelial cancer, lymphoma, multiple myeloma, cervical cancer, and other difficult-to-treat malignancies where patients often progress after standard therapies. The market is being shaped by the rapid evolution from first-generation ADCs toward more advanced platforms with improved antibodies, stable linkers, optimized drug-antibody ratios, bystander effect capability, and more potent payload classes. Topoisomerase I inhibitor-based ADCs have gained major attention due to strong clinical performance in solid tumors. At the same time, microtubule inhibitor ADCs continue to remain relevant across hematologic cancers and selected solid tumors. The growing diversity of payloads is improving the ability of developers to address tumors with different biology, resistance patterns, and antigen expression profiles.
Another major trend is the expansion of ADCs into earlier lines of therapy and combination regimens. Initially, many ADCs were positioned as later-line treatments for heavily pretreated patients. The commercial strategy is now shifting toward earlier treatment settings, biomarker-defined patient groups, and combinations with immune checkpoint inhibitors, targeted therapies, and endocrine therapies. This shift is important because earlier-line use can significantly increase eligible patient volumes, extend treatment duration, and improve long-term revenue potential. The market is also benefiting from major pharmaceutical partnerships, licensing deals, and acquisitions. Large oncology companies are actively building ADC portfolios because the modality offers both clinical differentiation and strong lifecycle management potential. With growing competition across HER2, TROP2, Nectin-4, B7-H3, c-Met, and other targets, companies are investing heavily in next-generation ADC design, companion diagnostics, manufacturing scale-up, and global commercialization.
MARKET DYNAMICS:
Driver: Rising Demand for Targeted Oncology and Expanding Solid Tumor Applications
The Antibody-Drug Conjugates Market is driven by the rising clinical need for targeted cancer medicines that provide higher efficacy and a better toxicity profile. Cancer treatment is evolving rapidly toward precision medicine, in which medicines are chosen based on the biology of the tumor, its biomarker status, antigen expression and resistance mechanisms. Here is where ADCs come in . They take advantage of tumor - associated antigen to deliver cytotoxic payloads in a more specific manner. The solid tumors market opportunity is rapidly expanding. Historically, success with ADCs has been limited to hematologic malignancies; however, recent approvals and late-stage trials have shown promise for breast cancer, lung cancer, urothelial cancer, cervical cancer, gastric cancer, and other tumor types. HER2-targeted ADCs have transformed the therapy landscape of breast cancer, while TROP2-directed ADCs are broadening the possibilities for breast and lung cancer patients. Nectin-4 ADCs have emerged in urothelial cancer and additional targets, including B7-H3 and c-Met, are opening new paths for growth.
The increased number of cancer patients relapsing after chemotherapy, immunotherapy or targeted therapy is further supporting demand. ADCs are widely seen as a compromise between conventional chemotherapy and precision oncology, offering substantial cytotoxic effect by a more selective method. This makes them intriguing for individuals who have limited therapy alternatives and for physicians who are looking for medicines that can work after resistance develops.
Restraint: Safety Management, Manufacturing Complexity, and High Development Cost
The ADC market confronts key restrains despite excellent development potential that are connected to safety, production and pricing. ADCs are complicated biologic-drug combinations that need precise control of the antibody synthesis, linker chemistry, payload potency, conjugation stability, and drug-antibody ratio. Manufacturing consistency is important since slight changes can influence safety, effectiveness, pharmacokinetics, and regulatory approval. This makes ADC development more costly and technically challenging than many traditional cancer medicines.
Safety is still a major problem. Although ADCs are more targeted than traditional chemotherapy, they can nevertheless induce major adverse events depending on the type of payload, expression of the target, dose schedule, and off-tumor effects. Prescribing behavior, dose change, and patient adherence may be affected by interstitial lung disease, neutropenia, neuropathy, eye toxicity, liver toxicity, and gastrointestinal adverse effects. Companies therefore have to invest in excellent clinical risk management, patient selection, monitoring techniques, and physician education. Cost and reimbursement are also factors in market adoption. ADCs are premium oncology treatments and healthcare systems must analyze therapeutic value, survival benefit, quality of life impact, and budget burden. With other ADCs entering similar indications, payers are likely to require more robust comparison evidence. Clear survival benefit, biomarker-defined positioning and distinct safety profiles are predicted to obtain stronger access.
Opportunity: Next-Generation Payloads, New Targets, and ADC Combination Strategies
The development of next-generation ADCs that are able to overcome the constraints that are now present in terms of efficacy, toxicity, and resistance provide the greatest and most promising prospect. They are studying novel payload categories such as DNA damaging compounds, immune boosting payloads, protein degraders, and tailored cytotoxic mechanisms beyond conventional microtubule inhibitors. These advances could open the door to ADCs for malignancies that have been less responsive to existing payloads.
Another big opportunity is new target discovery. HER2 and TROP2 have become very competitive spaces but new targets such as B7-H3, c-Met, HER3, CLDN18.2, FRα, tissue factor and ROR1 are opening up new commercial routes. Antigen expression, rate of internalization, tumor selectivity and resistance biology are directly impacting ADC performance therefore target selection will continue to be a critical differentiator. Combination methods are also predicted to unlock high value growth. ADCs are being widely tested in combination with immune checkpoint inhibitors, PARP inhibitors, endocrine treatments and targeted medicines. These combinations may increase response rates and broaden the usage of ADCs to earlier lines of treatment. Those companies who are able to provide solid combo data and get label expansion for many indications will be best placed for long-term market leadership.
SEGMENT ANALYSIS:
HER2 and TROP2 Targeted ADCs Are Leading Commercial Growth
By target antigen, HER2 and TROP2 targeted ADCs are projected to remain among of the top revenue-generating sectors. HER2-directed ADCs have created enormous clinical and commercial momentum in breast cancer and are now spreading into gastric, lung and other HER2-expressing malignancies. The success of HER2 ADCs has validated the ADC platform more broadly and has spurred businesses to study other tumor-associated antigens. TROP2-targeted ADCs are developing as one of the most important growth areas due to the widespread expression of TROP2 in breast cancer, lung cancer, and other epithelial cancers. This target is intriguing because of support from huge patient populations and potential indication growth opportunities TROP2 ADCs are also emerging as an option to chemotherapy in patients who have had endocrine therapy, immunotherapy or targeted treatment.
Breast Cancer Remains the Largest Indication, While Lung Cancer Shows Strong Growth Potential
By cancer type, breast cancer is expected to remain the largest segment in the Antibody-Drug Conjugates Market. ADCs have become deeply integrated into breast cancer treatment, particularly across HER2-positive, HER2-low, HR-positive/HER2-negative, and triple-negative disease settings. The expansion of ADCs into earlier lines of therapy and broader biomarker populations is expected to support sustained revenue growth. Lung cancer is expected to show strong growth during the forecast period. Non-small cell lung cancer remains one of the largest oncology markets, and ADCs are gaining traction in biomarker-defined subgroups such as TROP2, c-Met, HER3, and B7-H3. Lung cancer is commercially attractive because of its high incidence, multiple therapy lines, and continued unmet need after targeted therapy and immunotherapy resistance.
REGIONAL ANALYSIS:
North America Leads the Market, While Asia-Pacific Is Set to Witness Significant Growth During the Forecast Period
North America is expected to remain the largest region in the Antibody-Drug Conjugates Market due to high oncology drug spending, strong clinical trial activity, early adoption of precision cancer therapies, advanced biomarker testing infrastructure, and the presence of leading pharmaceutical companies. The United States remains the key revenue contributor, supported by rapid uptake of newly approved ADCs, broad specialist access, and strong reimbursement for innovative oncology products. Asia-Pacific is expected to witness the fastest growth during the forecast period, driven by rising cancer incidence, expanding oncology infrastructure, growing access to targeted therapies, increasing domestic biotech innovation, and strong clinical development activity in China, Japan, South Korea, India, and Australia. The region is becoming increasingly important for ADC manufacturing, licensing, and late-stage clinical trials.
COMPETITIVE ANALYSIS:
The Antibody-Drug Conjugates Market is highly competitive and innovation-driven, with large pharmaceutical companies, established oncology leaders, and specialized biotechnology firms competing across target selection, linker-payload technology, clinical efficacy, safety, manufacturing capability, and global commercialization. The competitive landscape is moving beyond single-product success toward full ADC platform strategies. Top 10 companies include:
Daiichi Sankyo Company, Limited
AstraZeneca plc
Pfizer Inc.
Gilead Sciences, Inc.
Roche / Genentech
AbbVie Inc.
Astellas Pharma Inc.
Merck & Co., Inc.
BioNTech SE
Genmab A/S
RECENT DEVELOPMENTS
April 2026: Daiichi Sankyo and Merck announced that the U.S. FDA granted Priority Review to ifinatamab deruxtecan, a B7-H3-directed DXd ADC, for adults with previously treated extensive-stage small cell lung cancer. If approved, the therapy could become a first-in-class B7-H3-directed ADC for this patient population.
May 2025: AbbVie received U.S. FDA accelerated approval for Emrelis, a c-Met-directed antibody-drug conjugate, for adults with previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression. The approval added a new targeted ADC option for a biomarker-defined lung cancer population.
January 2025: The U.S. FDA approved Daiichi Sankyo and AstraZeneca’s Datroway for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer after prior endocrine-based therapy and chemotherapy. The approval strengthened the commercial position of TROP2-directed ADCs in breast cancer treatment.
SCOPE OF THE MARKET:
By Target Antigen
Gain complete market intelligence on the Antibody-Drug Conjugates Market: This report provides a strategic view of market size, CAGR outlook, demand trends, revenue forecast, clinical adoption patterns, regional growth, and commercialization opportunities across ADC oncology therapies.
Identify high-growth target and payload opportunities: The study helps pharmaceutical companies, biotech firms, investors, licensing teams, and oncology strategists assess growth potential across HER2, TROP2, Nectin-4, c-Met, B7-H3, topoisomerase I inhibitor payloads, microtubule inhibitor payloads, and next-generation ADC platforms.
Support pipeline, partnership, and investment decisions: The report highlights where competition is moving across target antigen, payload type, and cancer indication, helping stakeholders evaluate attractive opportunities in breast cancer, lung cancer, urothelial cancer, hematologic malignancies, and emerging biomarker-defined tumors.
Understand competitive positioning and innovation direction: The report evaluates leading ADC companies such as Daiichi Sankyo, AstraZeneca, Pfizer, Gilead Sciences, Roche/Genentech, AbbVie, Astellas, Merck, BioNTech, and Genmab, enabling stakeholders to benchmark portfolios, pipeline strength, and strategic focus.
Make informed decisions with future-ready ADC market insights: This report supports decision-makers seeking opportunities in precision oncology, targeted chemotherapy delivery, linker-payload innovation, companion diagnostics, solid tumor expansion, ADC combinations, and global oncology commercialization through 2034.
The global Antibody-Drug Conjugates Market is expected to expand at a CAGR of 14.7% from 2026 to 2034, driven by the rising demand for targeted oncology therapies, increasing approvals of next-generation ADCs, growing adoption across solid tumors, and strong pharmaceutical investment in linker-payload innovation. Antibody-drug conjugates have moved from a niche oncology modality into one of the most commercially attractive areas of cancer therapeutics, as they combine the targeting ability of monoclonal antibodies with the cell-killing strength of highly potent cytotoxic payloads.
ADCs are designed to deliver chemotherapy-like agents directly to cancer cells while reducing exposure to healthy tissues. This targeted delivery model addresses a long-standing limitation in oncology: achieving strong tumor control without the systemic toxicity associated with conventional chemotherapy. The technology has become especially important in breast cancer, lung cancer, urothelial cancer, lymphoma, multiple myeloma, cervical cancer, and other difficult-to-treat malignancies where patients often progress after standard therapies. The market is being shaped by the rapid evolution from first-generation ADCs toward more advanced platforms with improved antibodies, stable linkers, optimized drug-antibody ratios, bystander effect capability, and more potent payload classes. Topoisomerase I inhibitor-based ADCs have gained major attention due to strong clinical performance in solid tumors. At the same time, microtubule inhibitor ADCs continue to remain relevant across hematologic cancers and selected solid tumors. The growing diversity of payloads is improving the ability of developers to address tumors with different biology, resistance patterns, and antigen expression profiles.
Another major trend is the expansion of ADCs into earlier lines of therapy and combination regimens. Initially, many ADCs were positioned as later-line treatments for heavily pretreated patients. The commercial strategy is now shifting toward earlier treatment settings, biomarker-defined patient groups, and combinations with immune checkpoint inhibitors, targeted therapies, and endocrine therapies. This shift is important because earlier-line use can significantly increase eligible patient volumes, extend treatment duration, and improve long-term revenue potential. The market is also benefiting from major pharmaceutical partnerships, licensing deals, and acquisitions. Large oncology companies are actively building ADC portfolios because the modality offers both clinical differentiation and strong lifecycle management potential. With growing competition across HER2, TROP2, Nectin-4, B7-H3, c-Met, and other targets, companies are investing heavily in next-generation ADC design, companion diagnostics, manufacturing scale-up, and global commercialization.
MARKET DYNAMICS:
Driver: Rising Demand for Targeted Oncology and Expanding Solid Tumor Applications
The Antibody-Drug Conjugates Market is driven by the rising clinical need for targeted cancer medicines that provide higher efficacy and a better toxicity profile. Cancer treatment is evolving rapidly toward precision medicine, in which medicines are chosen based on the biology of the tumor, its biomarker status, antigen expression and resistance mechanisms. Here is where ADCs come in . They take advantage of tumor - associated antigen to deliver cytotoxic payloads in a more specific manner. The solid tumors market opportunity is rapidly expanding. Historically, success with ADCs has been limited to hematologic malignancies; however, recent approvals and late-stage trials have shown promise for breast cancer, lung cancer, urothelial cancer, cervical cancer, gastric cancer, and other tumor types. HER2-targeted ADCs have transformed the therapy landscape of breast cancer, while TROP2-directed ADCs are broadening the possibilities for breast and lung cancer patients. Nectin-4 ADCs have emerged in urothelial cancer and additional targets, including B7-H3 and c-Met, are opening new paths for growth.
The increased number of cancer patients relapsing after chemotherapy, immunotherapy or targeted therapy is further supporting demand. ADCs are widely seen as a compromise between conventional chemotherapy and precision oncology, offering substantial cytotoxic effect by a more selective method. This makes them intriguing for individuals who have limited therapy alternatives and for physicians who are looking for medicines that can work after resistance develops.
Restraint: Safety Management, Manufacturing Complexity, and High Development Cost
The ADC market confronts key restrains despite excellent development potential that are connected to safety, production and pricing. ADCs are complicated biologic-drug combinations that need precise control of the antibody synthesis, linker chemistry, payload potency, conjugation stability, and drug-antibody ratio. Manufacturing consistency is important since slight changes can influence safety, effectiveness, pharmacokinetics, and regulatory approval. This makes ADC development more costly and technically challenging than many traditional cancer medicines.
Safety is still a major problem. Although ADCs are more targeted than traditional chemotherapy, they can nevertheless induce major adverse events depending on the type of payload, expression of the target, dose schedule, and off-tumor effects. Prescribing behavior, dose change, and patient adherence may be affected by interstitial lung disease, neutropenia, neuropathy, eye toxicity, liver toxicity, and gastrointestinal adverse effects. Companies therefore have to invest in excellent clinical risk management, patient selection, monitoring techniques, and physician education. Cost and reimbursement are also factors in market adoption. ADCs are premium oncology treatments and healthcare systems must analyze therapeutic value, survival benefit, quality of life impact, and budget burden. With other ADCs entering similar indications, payers are likely to require more robust comparison evidence. Clear survival benefit, biomarker-defined positioning and distinct safety profiles are predicted to obtain stronger access.
Opportunity: Next-Generation Payloads, New Targets, and ADC Combination Strategies
The development of next-generation ADCs that are able to overcome the constraints that are now present in terms of efficacy, toxicity, and resistance provide the greatest and most promising prospect. They are studying novel payload categories such as DNA damaging compounds, immune boosting payloads, protein degraders, and tailored cytotoxic mechanisms beyond conventional microtubule inhibitors. These advances could open the door to ADCs for malignancies that have been less responsive to existing payloads.
Another big opportunity is new target discovery. HER2 and TROP2 have become very competitive spaces but new targets such as B7-H3, c-Met, HER3, CLDN18.2, FRα, tissue factor and ROR1 are opening up new commercial routes. Antigen expression, rate of internalization, tumor selectivity and resistance biology are directly impacting ADC performance therefore target selection will continue to be a critical differentiator. Combination methods are also predicted to unlock high value growth. ADCs are being widely tested in combination with immune checkpoint inhibitors, PARP inhibitors, endocrine treatments and targeted medicines. These combinations may increase response rates and broaden the usage of ADCs to earlier lines of treatment. Those companies who are able to provide solid combo data and get label expansion for many indications will be best placed for long-term market leadership.
SEGMENT ANALYSIS:
HER2 and TROP2 Targeted ADCs Are Leading Commercial Growth
By target antigen, HER2 and TROP2 targeted ADCs are projected to remain among of the top revenue-generating sectors. HER2-directed ADCs have created enormous clinical and commercial momentum in breast cancer and are now spreading into gastric, lung and other HER2-expressing malignancies. The success of HER2 ADCs has validated the ADC platform more broadly and has spurred businesses to study other tumor-associated antigens. TROP2-targeted ADCs are developing as one of the most important growth areas due to the widespread expression of TROP2 in breast cancer, lung cancer, and other epithelial cancers. This target is intriguing because of support from huge patient populations and potential indication growth opportunities TROP2 ADCs are also emerging as an option to chemotherapy in patients who have had endocrine therapy, immunotherapy or targeted treatment.
Breast Cancer Remains the Largest Indication, While Lung Cancer Shows Strong Growth Potential
By cancer type, breast cancer is expected to remain the largest segment in the Antibody-Drug Conjugates Market. ADCs have become deeply integrated into breast cancer treatment, particularly across HER2-positive, HER2-low, HR-positive/HER2-negative, and triple-negative disease settings. The expansion of ADCs into earlier lines of therapy and broader biomarker populations is expected to support sustained revenue growth. Lung cancer is expected to show strong growth during the forecast period. Non-small cell lung cancer remains one of the largest oncology markets, and ADCs are gaining traction in biomarker-defined subgroups such as TROP2, c-Met, HER3, and B7-H3. Lung cancer is commercially attractive because of its high incidence, multiple therapy lines, and continued unmet need after targeted therapy and immunotherapy resistance.
REGIONAL ANALYSIS:
North America Leads the Market, While Asia-Pacific Is Set to Witness Significant Growth During the Forecast Period
North America is expected to remain the largest region in the Antibody-Drug Conjugates Market due to high oncology drug spending, strong clinical trial activity, early adoption of precision cancer therapies, advanced biomarker testing infrastructure, and the presence of leading pharmaceutical companies. The United States remains the key revenue contributor, supported by rapid uptake of newly approved ADCs, broad specialist access, and strong reimbursement for innovative oncology products. Asia-Pacific is expected to witness the fastest growth during the forecast period, driven by rising cancer incidence, expanding oncology infrastructure, growing access to targeted therapies, increasing domestic biotech innovation, and strong clinical development activity in China, Japan, South Korea, India, and Australia. The region is becoming increasingly important for ADC manufacturing, licensing, and late-stage clinical trials.
COMPETITIVE ANALYSIS:
The Antibody-Drug Conjugates Market is highly competitive and innovation-driven, with large pharmaceutical companies, established oncology leaders, and specialized biotechnology firms competing across target selection, linker-payload technology, clinical efficacy, safety, manufacturing capability, and global commercialization. The competitive landscape is moving beyond single-product success toward full ADC platform strategies. Top 10 companies include:
Daiichi Sankyo Company, Limited
AstraZeneca plc
Pfizer Inc.
Gilead Sciences, Inc.
Roche / Genentech
AbbVie Inc.
Astellas Pharma Inc.
Merck & Co., Inc.
BioNTech SE
Genmab A/S
RECENT DEVELOPMENTS
April 2026: Daiichi Sankyo and Merck announced that the U.S. FDA granted Priority Review to ifinatamab deruxtecan, a B7-H3-directed DXd ADC, for adults with previously treated extensive-stage small cell lung cancer. If approved, the therapy could become a first-in-class B7-H3-directed ADC for this patient population.
May 2025: AbbVie received U.S. FDA accelerated approval for Emrelis, a c-Met-directed antibody-drug conjugate, for adults with previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression. The approval added a new targeted ADC option for a biomarker-defined lung cancer population.
January 2025: The U.S. FDA approved Daiichi Sankyo and AstraZeneca’s Datroway for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer after prior endocrine-based therapy and chemotherapy. The approval strengthened the commercial position of TROP2-directed ADCs in breast cancer treatment.
SCOPE OF THE MARKET:
By Target Antigen
- HER2
- TROP2
- Nectin-4
- CD30/CD33
- Others
- Topoisomerase I Inhibitors
- Microtubule Inhibitors
- DNA-Damaging Agents
- Novel Payloads
- Others
- Breast Cancer
- Lung Cancer
- Urothelial Cancer
- Hematologic Malignancies
- Others
- North America (United States & Canada)
- Europe (Germany, UK, France, Spain, Italy and Rest of Europe)
- Asia-Pacific (China, Japan, India, South Korea, Australia and Rest of Asia-Pacific)
- Latin America (Brazil, Mexico, Argentina and Rest of Latin America)
- Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa and Rest of Middle East and Africa)
Gain complete market intelligence on the Antibody-Drug Conjugates Market: This report provides a strategic view of market size, CAGR outlook, demand trends, revenue forecast, clinical adoption patterns, regional growth, and commercialization opportunities across ADC oncology therapies.
Identify high-growth target and payload opportunities: The study helps pharmaceutical companies, biotech firms, investors, licensing teams, and oncology strategists assess growth potential across HER2, TROP2, Nectin-4, c-Met, B7-H3, topoisomerase I inhibitor payloads, microtubule inhibitor payloads, and next-generation ADC platforms.
Support pipeline, partnership, and investment decisions: The report highlights where competition is moving across target antigen, payload type, and cancer indication, helping stakeholders evaluate attractive opportunities in breast cancer, lung cancer, urothelial cancer, hematologic malignancies, and emerging biomarker-defined tumors.
Understand competitive positioning and innovation direction: The report evaluates leading ADC companies such as Daiichi Sankyo, AstraZeneca, Pfizer, Gilead Sciences, Roche/Genentech, AbbVie, Astellas, Merck, BioNTech, and Genmab, enabling stakeholders to benchmark portfolios, pipeline strength, and strategic focus.
Make informed decisions with future-ready ADC market insights: This report supports decision-makers seeking opportunities in precision oncology, targeted chemotherapy delivery, linker-payload innovation, companion diagnostics, solid tumor expansion, ADC combinations, and global oncology commercialization through 2034.
Table of Contents
162 Pages
- 1. Executive Summary
- 1.1. Global Antibody-Drug Conjugates Market Outlook
- 1.1.1. Global Antibody-Drug Conjugates Market - Regional Analysis
- 1.1.2. Global Antibody-Drug Conjugates Market - Segment Analysis
- 1.1.3. Global Antibody-Drug Conjugates Market - Competitive Snapshot
- 1.2. Technology Roadmap Analysis
- 1.3. Market Opportunity Assessment
- 1.4. Key Investment Pockets
- 1.5. Analyst Recommendation
- 2. Overview And Scope
- 2.1. Market Coverage
- 2.2. Market Definition
- 2.3. Market Segmentation
- 2.4. Report Assumptions
- 2.5. Currency and Forecasting Parameters
- 3. Global Antibody-Drug Conjugates Market Overview, By Region: 2020 Vs 2025 Vs 2034
- 3.1. Global Antibody-Drug Conjugates Market, By Region (2020 VS 2025 VS 2034)
- 3.2. North America Antibody-Drug Conjugates Market, By Country (2020 VS 2025 VS 2034)
- 3.3. Europe Antibody-Drug Conjugates Market, By Country (2020 VS 2025 VS 2034)
- 3.4. Asia-Pacific Antibody-Drug Conjugates Market, By Country (2020 VS 2025 VS 2034)
- 3.5. Latin America Antibody-Drug Conjugates Market, By Country (2020 VS 2025 VS 2034)
- 3.6. Middle East & Africa Antibody-Drug Conjugates Market, By Country (2020 VS 2025 VS 2034)
- 4. Global Antibody-Drug Conjugates Market Dynamics
- 4.1. Market Overview
- 4.1.1. Market Drivers
- 4.1.2. Market Restraints/Challenges Analysis
- 4.1.3. Market Opportunities
- 4.2. PESTLE Analysis
- 4.3. Value Chain Analysis/Supply Chain Analysis
- 4.4. Porter’s Five Forces Model
- 4.5. Regulatory Landscape
- 4.6. Pricing Model Analysis
- 4.7. Technology Trend Analysis
- 4.8. Impact of AI, Biomarker Testing and Precision Oncology on Market Growth
- 4.9. ESG and Sustainability Impact Analysis
- 5. Global Antibody-Drug Conjugates Market, By Target Antigen
- 5.1. Introduction / Key Findings
- 5.2. Global Antibody-Drug Conjugates Market By Target Antigen (2020 - 2034) (USD Million)
- 5.3. Key Findings for Antibody-Drug Conjugates Market - By Target Antigen
- 5.3.1. HER2
- 5.3.2. TROP2
- 5.3.3. Nectin-4
- 5.3.4. CD30/CD33
- 5.3.5. Others
- 6. Global Antibody-Drug Conjugates Market, By Payload Type
- 6.1. Overview
- 6.2. Global Antibody-Drug Conjugates Market By Payload Type (2020 - 2034) (USD Million)
- 6.3. Key Findings for Antibody-Drug Conjugates Market - By Payload Type
- 6.3.1. Topoisomerase I Inhibitors
- 6.3.2. Microtubule Inhibitors
- 6.3.3. DNA-Damaging Agents
- 6.3.4. Novel Payloads
- 6.3.5. Others
- 7. Global Antibody-Drug Conjugates Market, By Cancer Type
- 7.1. Overview
- 7.2. Global Antibody-Drug Conjugates Market By Cancer Type (2020 - 2034) (USD Million)
- 7.3. Key Findings for Antibody-Drug Conjugates Market - By Cancer Type
- 7.3.1. Breast Cancer
- 7.3.2. Lung Cancer
- 7.3.3. Urothelial Cancer
- 7.3.4. Hematologic Malignancies
- 7.3.5. Others
- 8. Global Antibody-Drug Conjugates Market, By Region
- 8.1. Overview
- 8.2. Global Antibody-Drug Conjugates Market, By Region (2020 - 2034) (USD Million)
- 8.3. Key Findings For Antibody-Drug Conjugates Market - By Region
- 8.4. Global Antibody-Drug Conjugates Market, By Target Antigen
- 8.5. Global Antibody-Drug Conjugates Market, By Payload Type
- 8.6. Global Antibody-Drug Conjugates Market, By Cancer Type
- 9. Global Antibody-Drug Conjugates Market - North America
- 9.1. Overview
- 9.2. North America Antibody-Drug Conjugates Market (2020 - 2034) (USD Million)
- 9.3. North America Antibody-Drug Conjugates Market, By Target Antigen
- 9.4. North America Antibody-Drug Conjugates Market, By Payload Type
- 9.5. North America Antibody-Drug Conjugates Market, By Cancer Type
- 9.6. North America Antibody-Drug Conjugates Market by Country
- 9.6.1. United States
- 9.6.2. Canada
- 10. Global Antibody-Drug Conjugates Market - Europe
- 10.1. Overview
- 10.2. Europe Antibody-Drug Conjugates Market (2020 - 2034) (USD Million)
- 10.3. Europe Antibody-Drug Conjugates Market, By Target Antigen
- 10.4. Europe Antibody-Drug Conjugates Market, By Payload Type
- 10.5. Europe Antibody-Drug Conjugates Market, By Cancer Type
- 10.6. Europe Antibody-Drug Conjugates Market by Country
- 10.6.1. Germany
- 10.6.2. UK
- 10.6.3. France
- 10.6.4. Spain
- 10.6.5. Italy
- 10.6.6. Rest of Europe
- 11. Global Antibody-Drug Conjugates Market - Asia-Pacific
- 11.1. Overview
- 11.2. Asia-Pacific Antibody-Drug Conjugates Market (2020 - 2034) (USD Million)
- 11.3. Asia-Pacific Antibody-Drug Conjugates Market, By Target Antigen
- 11.4. Asia-Pacific Antibody-Drug Conjugates Market, By Payload Type
- 11.5. Asia-Pacific Antibody-Drug Conjugates Market, By Cancer Type
- 11.6. Asia-Pacific Antibody-Drug Conjugates Market by Country
- 11.6.1. China
- 11.6.2. Japan
- 11.6.3. India
- 11.6.4. South Korea
- 11.6.5. Australia
- 11.6.6. Rest of Asia-Pacific
- 12. Global Antibody-Drug Conjugates Market - Latin America
- 12.1. Overview
- 12.2. Latin America Antibody-Drug Conjugates Market (2020 - 2034) (USD Million)
- 12.3. Latin America Antibody-Drug Conjugates Market, By Target Antigen
- 12.4. Latin America Antibody-Drug Conjugates Market, By Payload Type
- 12.5. Latin America Antibody-Drug Conjugates Market, By Cancer Type
- 12.6. Latin America Antibody-Drug Conjugates Market by Country
- 12.6.1. Brazil
- 12.6.2. Mexico
- 12.6.3. Argentina
- 12.6.4. Rest Of Latin America
- 13. Global Antibody-Drug Conjugates Market - Middle East & Africa
- 13.1. Overview
- 13.2. Middle East & Africa Antibody-Drug Conjugates Market Size (2020 - 2034) (USD Million)
- 13.3. Middle East & Africa Antibody-Drug Conjugates Market, By Target Antigen
- 13.4. Middle East & Africa Antibody-Drug Conjugates Market, By Payload Type
- 13.5. Middle East & Africa Antibody-Drug Conjugates Market, By Cancer Type
- 13.6. Middle East & Africa Antibody-Drug Conjugates Market, By Country
- 13.6.1. Saudi Arabia
- 13.6.2. UAE
- 13.6.3. Israel
- 13.6.4. South Africa
- 13.6.5. Rest of Middle East & Africa
- 14. Global Antibody-Drug Conjugates Market - Competitive Landscape
- 14.1. Key Competitive Analysis
- 14.2. Key Strategies Adopted by the Leading Players
- 14.3. Global Antibody-Drug Conjugates Market Competitive Positioning
- 14.3.1. Important Performers
- 14.3.2. Emerging Innovators
- 14.3.3. Market Players with Moderate Innovation
- 14.4. Company Market Share Analysis
- 14.5. Product Benchmarking
- 14.6. Partnership, Merger and Acquisition Analysis
- 14.7. Recent Developments
- 15. Global Antibody-Drug Conjugates Market - Company Profiles
- 15.1. Daiichi Sankyo Company, Limited
- 15.1.1. Corporate Summary
- 15.1.2. Corporate Financial Review
- 15.1.3. Product Portfolio
- 15.1.4. Key Development
- 15.2. AstraZeneca plc
- 15.3. Pfizer Inc.
- 15.4. Gilead Sciences, Inc.
- 15.5. Roche / Genentech
- 15.6. AbbVie Inc.
- 15.7. Astellas Pharma Inc.
- 15.8. Merck & Co., Inc.
- 15.9. BioNTech SE
- 15.10. Genmab A/S
- 16. Our Research Methodology
- 16.1. Our Research Practice
- 16.2. Data Source
- 16.2.1. Secondary Source
- 16.2.2. Primary Source
- 16.3. Data Assumption
- 16.4. Analytical Framework for Market Assessment and Forecasting
- 16.5. Our Research Process
- 16.6. Data Validation and Publishing
- 17. Appendix
- 17.1. Disclaimer
- 17.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
